PRIMARY OBJECTIVES:. I. To determine the recommended Phase II dose of ABT-888 (veliparib) given in combination with pegylated liposomal doxorubicin (pegylated liposomal doxorubicin hydrochloride) (PLD - 40 mg/m2 every 4 weeks) in patients with ovarian or breast cancer.. SECONDARY OBJECTIVES:. I. To determine the toxicity profile of the ABT-888 plus PLD combination. II. To determine the effects of ABT-888 on the pharmacokinetics of PLD. III. To determine the efficacy of ABT-888 plus PLD in ovarian and breast cancer.. OUTLINE: This is a dose-escalation study of veliparib.. Patients receive veliparib orally (PO) twice daily (BID) on days 1-14 and pegylated liposomal doxorubicin hydrochloride intravenously (IV) over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.. After completion of study therapy, patients are followed up every 3 months for 1 year and then every 6 months for 2 years. ...
PRIMARY OBJECTIVE:. I. To evaluate the complete response (CR) + near-complete response (nCR) rate of the bortezomib/pegylated liposomal doxorubicin (pegylated liposomal doxorubicin hydrochloride) regimen in patients with previously untreated, symptomatic multiple myeloma.. II. To evaluate the toxicity of the bortezomib/pegylated liposomal doxorubicin regimen in patients with previously untreated, symptomatic multiple myeloma.. SECONDARY OBJECTIVES:. I. To evaluate the overall response rate, including patients with CR, nCR, and partial response (PR), of the bortezomib/pegylated liposomal doxorubicin regimen in patients with previously untreated, symptomatic multiple myeloma.. II. To evaluate the impact of therapy with the bortezomib/pegylated liposomal doxorubicin regimen on the ability to collect peripheral blood stem cells in those patients going on to subsequent autologous stem cell transplantation.. III. To evaluate the time to progression (TTP) in all patients receiving bortezomib/pegylated ...
Objective: To estimate the short-term healthcare costs and incremental cost per event avoided, associated with aggressive atorvastatin treatment in patients with acute coronary syndrome in Sweden. Methods: The total expected 16-week healthcare costs per patient on atorvastatin 80 mg per day and placebo were compared using clinical outcomes data from The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study and Swedish cost data sources. The incremental cost per event avoided was also assessed for. The clinical outcomes measured in this pharmacoeconomic analysis included: death, cardiac arrest, non-fatal myocardial infarction, fatal myocardial infarction, angina pectoris, non-fatal stroke, congestive heart failure, and surgical or percutaneous coronary revascularizations. All direct medical costs were taken into account. Results: The probability of the occurrence of an event was 40.4% per patient in the placebo cohort and 36.6% per patient in the atorvastatin cohort. ...
Objective: To perform a pharmacoeconomic analysis on the treatment of chronic obstructive pulmonary disease (COPD) with the addition of tiotropium bromide. Methods: Pharmacoeconomic modeling was performed utilizing the efficacy of tiotropium bromide from the literature on different settings and severity of COPD. Reductions in exacerbations, hospitalizations, and number of exacerbation days per year were derived from these studies. Cost of drug treatment, exacerbations, hospitalization, and loss of income were derived from local data in Singapore and reported in Singapore dollars (US$1=S$1.71). A model was constructed to calculate the impact of one-year treatment with tiotropium bromide, and the results were reported for the total incremental cost per year, cost per year needed to reduce one hospitalization in one year, and cost-savings from hospitalizations in one year. Sensitivity analysis were performed for different number of patients treated per year, differing cost of hospitalization, ...
PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Research interests to date include pharmacoeconomic evaluation, value of information analysis, multiple criteria decision analysis, survival analysis, cost of care studies and analysis of drug utilisation and expenditure in the real world setting. Laura is part of a collaborative team (including the University of Limerick, the National Cancer Registry and the NCPE)which has been awarded a HRB APA grant to examine how analysis of drug utilisation and real world outcomes databases can support pharmacoeconomic evaluations. Further, Laura is a Co-Applicant on a HRB RCQPS Award which is investigating how a GP practice-based Pharmacist Medicines Optimisation Programme might support prescribing in Irish primary care. Laura has published widely in peer reviewed journals and has presented her research at National, European and International Conferences. She has provided peer-review for a number of journals including: Value in Health, PharmacoEconomics, The European Journal of Health Economics, Thrombosis ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
The cost of emergency department services has become a major concern for patients, providers, and payers. Solid economic information is needed to provide a rationale for the selection of therapeutic options and the provision of care that is both clinically and financially prudent. To assess the full cost of care for patients with seizures who...
Infections in orthopedic surgery are large problem in the medicine and are present all around the world.The main objective of the antibiotic prophylaxis in orthopedic surgeries is to prevent infection during the surgical intervention with antimicrobial agent that is safe, effective, and has a spectrum of activity that covers the most common pathogens that may occur during surgical procedures. Rational use of antibiotic prophylaxis in orthopedic surgeries has an important role in the prevention of the surgical infection. Patients who have undergone orthopedic surgery represent a high-risk group for postoperative infection. ...
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you dont have an account you can just enter your email address in the email box below ...
International Journal of Biological & Pharmaceutical Research (IJBPR) is a monthly international journal ... Indian Journal of Pharmaceutical Science & Research (IJPSR) is a bi-annual journal publishing the finest ... The Journal of Fundamental Pharmaceutical Research (JFPR) is an international, multidisciplinary peer-reviewed ...
PharmacoEconomics is the benchmark journal for peer-reviewed, authoritative and practical articles on the application of pharmacoeconomics and quality-of-life assessment to optimum drug therapy and health outcomes. An invaluable ...
A form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin. Liposomal doxorubicin hydrochloride is used to treat ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma in patients whose disease has not gotten better after treatment with other anticancer drugs. It may be used together with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Liposomal doxorubicin hydrochloride is a type of anthracycline antitumor antibiotic. Also called Dox-SL, Doxil, doxorubicin hydrochloride liposome, Evacet, and LipoDox ...
In recent years, more and more Japanese pharmaceutical companies have been submitting pharmacoeconomic data to the government. following the official request that such data may help in setting...
Restricted Access Oops, it looks like you dont have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following. ...
Background. A postoperative troponin leak that was previously considered clinically insignificant has been independently associated with 30-day mortality in unselected surgical patients ≥45 years of age following non-cardiac surgery. Objectives. To determine whether routine troponin surveillance following non-cardiac surgery and initiation of aspirin and statin therapy in troponin-positive patients is cost-effective. Methods. Pharmacoeconomic analysis to determine the cost-effectiveness of routine postoperative surveillance for patients aged ≥45 years undergoing non-cardiac surgery. We compared the total expected cost of hospital care of patients who received routine troponin surveillance and subsequent introduction of statin and aspirin therapy for 30 days in troponin-positive patients with the cost of hospital care of patients who did not receive troponin surveillance. We estimated a 25% relative risk reduction following statin and aspirin therapy for postoperative vascular mortality and non-fatal
Introduction Pharmaco-economic data on the management of knee osteoarthritis (OA) with intra articular hyaluronic acid (IA HA) viscosupplementation is limited. We contrasted IA HA with non-steroidal anti-inflammatory drugs (NSAIDs). Methods Observational, prospective and multicenter study comparing treatments of knee OA costs and efficacy with either NSAIDs alone, or hyaluronic acid (Arthrum H 2%®), during a 6-month follow-up period. The investigators were pharmacists who recorded data on disease, drug consumption and healthcare circuit. Retrospectively, the 6-month period preceding inclusion was also studied, to ensure the comparability of groups. Results 199 patients were analyzed in a NSAIDs group and 202 in an IA HA group. Any of the WOMAC sub-scores and the EQ-5D Quality of Life index were significantly improved in the IA HA group (p|0.0001) at 3 and 6 months. Clinical results were therefore in favor of the IA HA group. The total drug expenses per 6-month period were comparable before and
RTI uses cookies to offer you the best experience online. By continuing to use our website, you agree to the use of cookies. If you would like to know more about cookies and how to manage them please view our Privacy Policy. Close ...
Cell Culture In Pharmaceutical Research - Read Online or Download Cell Culture In Pharmaceutical Research by Tamara Holloway Book For Free. Available forma: PDF, TXT , ePub , PDB , RTF, Audio Books
Understanding Health Outcomes and Pharmacoeconomics George E. MacKinnon III, PhD, RPh, FASHP Principal, HealthKey Solutions, Inc. Founding Dean and Professor College of Pharmacy Roosevelt University Schaumburg
Find all books from Rychlik, Reinhard; Wertheimer, Albert I. - Strategies in Pharmacoeconomics and Outcomes Research. At find-more-books.com you can find used, antique and new books, COMPARE results and immediately PURCHASE your selection at the best price. 9780789015853
Source: PharmacoEconomics and Outcomes News - May 1, 2020 Category: Drugs & Pharmacology Source Type: news. Costs in warfarin-sensitive versus warfarin-insensitive patients ...
I am quite honored to come and deliver a quick presentation for you on the pharmacoeconomics of HIV treatment. First, a little bit about my background: In ...
The purpose of this report is to assess the cost-effectiveness of azithromycin monotherapy for hospitalized patients with community acquired pneumonia against the current practice of a second generation cephalosporin withwithout erythromycin. A pharmacoeconomic analysis from the hospital perspective was performed on 266 evaluable patients from a multicenter clinical trial which was conducted from 1993-1995. No significant differences in clinical success or adverse events rates were detected. Health care resource utilization was extracted from the data base were transformedconverted to national costs. A sensitivity analysis was performed and statistics applied to the cost-effectiveness ratios.
Structured comparison of pharmacoeconomic analyses for ACEIs and ARBs in patients with type 2 diabetic nephropathy is still lacking. This review aims to systematically review the cost-effectiveness of both ACEIs and ARBs in type 2 diabetic patients with nephropathy. A systematic literature search was performed in MEDLINE and EMBASE for the period from November 1, 1999 to Oct 31, 2011. Two reviewers independently assessed the quality of the articles included and extracted data. All cost-effectiveness results were converted to 2011 Euros. Up to October 2011, 434 articles were identified. After full-text checking and quality assessment, 30 articles were finally included in this review involving 39 study settings. All 6 ACEIs studies were literature-based evaluations which synthesized data from different sources. Other 33 studies were directed at ARBs and were designed based on specific trials. The Markov model was the most common decision analytic method used in the evaluations. From the cost-effectiveness
Gain the knowledge needed to navigate the pharmacy industry through our regulatory affairs, health policy, and pharmaceutic economics programs.
Pharmaceutical Research ImpactManufacturing is a very important component in getting safe drugs to patients. In fact, it is a critical step in the chain of very complex supply chain before a drug reaches the pharmacy shelves. When any critical link is broken, it opens the door for something like the heparin crisis where unsafe drugs led to the death of several patients.
Iranian Journal of Pharmaceutical Research , مجله ایرانی تحقیقات دارویی , IJPR , Drug , دارو , Pharmacy , Pharmaceutical
Iranian Journal of Pharmaceutical Research , مجله ایرانی تحقیقات دارویی , IJPR , Drug , دارو , Pharmacy , Pharmaceutical
Health,Albany NY (PRWEB) April 28 2013 GBI Research leading business intelligence provider has released its latest report Cloud Computing in Pharmaceutical Research and Development Virtualization of Data through the Cloud Optimizes Next-Generation DNA Sequencing and Clinical Trials Data Management which provides insights into the key applications of cloud computi,Cloud,Computing,in,Pharmaceutical,Research,and,Development,-,Virtualization,of,Data,through,the,Cloud,Optimizes,Next-Generation,DNA,Sequencing,and,Clinical,Trials,Data,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
... 100.mL of 1.00 M a phosphate buffer solution of pH = 7.45. The pKa of H2PO4− is 7.21. You have 2.00 L of 1.00 M KH2PO4 solution and 1.50 L of 1.00 M K2HPO4 solution, as well as a carboy of pure distilled H2O. How much 1.00 M KH2PO4 will you need to make this solution? ...
Introduction:. Dr. Schondelmeyer is a professor of Pharmaceutical Economics in the College of Pharmacy at the University of Minnesota where he holds the Century Mortar Club Endowed Chair in Pharmaceutical Management & Economics. Dr. Schondelmeyer is the Director of the PRIME Institute, which focuses on pharmaceutical research related to management and economics. He also serves as Head of the Department of Pharmaceutical Care & Health Systems.. Experience:. Dr. Schondelmeyers education, experience, and background provide him with a unique understanding of the complex and technical issues leading to dramatic changes in the pharmaceutical marketplace. His expertise includes pharmacy practice management, prescription drug reimbursement, drug benefit plan management, pricing patterns of the pharmaceutical industry, and pharmacoeconomics and outcomes management. His work experience has encompassed activities in practice, academia, professional associations, and state and federal government. ...
Three economic evaluations of pandemic influenza A (H1N1) vaccination campaigns in North America concluded that the mass vaccination campaigns would be, or were, highly cost-effective, if not cost-saving. This paper re-assesses each study's analysis and presents three arguments: 1) prediction of vaccine program cost-effectiveness is unrealistic, if not impossible, unless quality surveillance data is available; 2) even when surveillance data is available, vaccine cost-effectiveness calculations can still vary dramatically and need to undergo wider-ranging sensitivity analysis; 3) H1N1 vaccination campaigns in North America were likely not as cost-effective as previously thought. Several recommendations are then made for improving transparency, accuracy, portability, and sensitivity analysis in pharmacoeconomic studies more generally.   Key words: Pandemic, influenza, vaccination, immunization, cost-effectiveness, health economics, pharmaco-economics.
This study will be a multicentre randomized, open-label, phase IIIb study. This study will evaluate two different techniques of sedation: an analgesia based
Assessments of the direct and indirect costs of cancer treatment have demonstrated the extreme complexity of these costs. Expenditure on cancer treatment is high, often reaching 3 to 6% of the gross...
The objective of this study was to evaluate a new multidisciplinary process in which intravenous alteplase (tPA) waste, used for acute ischemic stroke (AIS), was salvaged in an attempt to maximize cost effectiveness without impacting door-to-needle (DTN) administration times....
Empagliflozin (EMPA)/metformin (MET) fixed-dose combination (FDC) tablet (Synjardy) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone, MET and a sulfonylurea (SU), MET and pioglitazone (PIO), or MET and insulin; or when EMPA and MET are already being co-administered as separate tablets with or without an SU, PIO, or insulin. The manufacturer is seeking reimbursement for adult patients with T2DM who are already stabilized on therapy with MET and EMPA, to replace the individual ...
ISSN 2312-2862. The journal is included in Russian Science Citation Index (RSCI);. Journal data are published on website of Russian General Scientific Electronic Library. Publication of manuscripts is free for post-graduate students.. The reprint of materials of number without the written sanction of editors is illegal.. Edition does not bear the responsibility for reliability of the information which contains in advertising materials.. The opinion of edition not necessarily coincides with opinion of the authors. Subscription index in the catalogue «Russian Post» 92646. ...
Schizophrenia is arguably the worst disease affecting humankind, costly in both social and financial terms. In the current cost-cutting climate, the focus is on economizing the delivery of health care, including reducing access to prescription drugs. Yet decreasing expenditures on drugs for severe illnesses, such as schizophrenia, is a false...
You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy. ...
Craig Thompson, Executive Director of AIDS Project Los Angeles, shares his perspective on the impact current financial constraints are having on patient ...
Disclosure: The Harvard Program on the Economic Evaluation of Medical Technology has received funding from Merck (unrestricted funds, unrelated to cholesterol-lowering drugs). Drs. Weinstein and Goldman were co-investigators for the economic substudy of the CARE study of pravastatin funded by Bristol-Myers Squibb.. Grant Support: By grant R01 HS 06258 from the Agency for Healthcare Research and Quality, unrestricted funds from the Harvard Program on the Economic Evaluation of Medical Technology (Ms. Prosser), National Library of Medicine Training Grant 5T15LM07092-08 (Ms. Prosser), and a Faculty Development Award in Pharmacoeconomics from the Pharmaceutical Research and Manufacturers of America Foundation (Dr. Stinnett).. Requests for Single Reprints: Milton C. Weinstein, PhD, Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115-5924.. Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; ...
Oslo Economics has produced an analysis on the economics of health of using NT-proBNP for diagnostics and treatment of patients... ...
Better Health is a network of healthcare professional blogs, offering commentary on news, research, health policy, healthcare reform, true stories, disease management and expert interviews.
Medlab Clinical Limited is engaged in the sale of nutraceutical products and pharmaceutical research. The Company operates through two segments: Nutraceutical and Pharmaceutical Research. Its Manuka-C is scientifically formulated to support optimal immune system function and includes evidence-based ingredients containing a blend of over three ascorbates combined with glutathione and Manuka honey powder. Its NOS NITRIC OXIDE SUPPORT is a pre-exercise sports food containing a selection of evidence-based ingredients combined to support and optimize exercise performance. Its Saccharomyces cerevisiae ssp. boulardii (SB) 5B is a probiotic yeast that helps to maintain gastrointestinal function and integrity by supporting a healthy gut microbial profile; by increasing the production of secretory Immunoglobulin A (sIgA), short-chain fatty acids (SCFAs) and helping to promote the activity of brush border disaccharide enzymes. It also offers Mg Optima and BioClean EPA:DHA + CoQ10.. medlab.co. ...
Practical advice, tutorials, and peer-reviewed research on liquid chromatography (HPLC), gas chromatography (GC), mass spectrometry (MS) and related techniques.
In 1999, the laboratory was awarded by the prestigious French Academy of Science. The research on several pathologies without real treatment have allowed this reward. Since then Vitrobio continues to increase its research to improve results. By 2016 its scientific advances have allowed the laboratory to be nominated to receive the remarkable distinction of the Galien award.. ...
The book also describes new trends in these areas. It introduces the fundamentals of CE and is aimed at beginners in this field. It clearly outlines the procedures used to mitigate several barriers, such as detection limits, signal detection, changing capillary environment, resolution separation of analytes, and hyphenation of mass spectrometry with CE, for a range of analytical problems. Each chapter outlines a specific electrophoretic variant with detailed instructions and some standard operating procedures. Where necessary, the authors summarize the reported works in tables. All in all, this book provides a comparative assessment of related techniques on mode selection, method development, detection, and quantitative analysis and estimation of pharmacokinetic parameters and broadens the understanding of modern CE applications, developments, and future prospects. In that respect, the book meets its desired goal of rendering assistance to lovers of electrophoresis. ...
They are inert, smelly and upsetting to look at-its a wonder that dead bodies are in such high demand. But for medical students they are an indispensable learning tool. In the 19th century some medical schools hired body snatchers to dig up the deceased… ...
The 13th annual Training Program in Health Outcomes and Pharmacoeconomic Research was held Sept. 23-26, 2013, at the Marriott University Park. Twenty-one attendees participated in the program and represented pharmaceutical companies, managed health care organizations and academia. Eight graduate students from the UA College of Pharmacy also attended various sessions throughout the week. The program consisted of a combination of lectures and hands-on workshops.. Interactive sessions included: ...